Charles River Laboratories is to buy Wuxi PharmaTech for $1.6bn, as it anticipates sharply rising demand for outsourced early-stage research from large pharmaceuticals companies.
Charles River Laboratories將以16億美元收購無錫藥明康德(WuXi AppTec)，因其預(yù)期大型制藥企業(yè)外包初期研究的需求將急劇上升。
您已閱讀10%（258字），剩余90%（2252字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。